Enliven Therapeutics is a cash-burning pre-revenue biotech with strong technical momentum — a golden cross, rising volume accumulation, and a 23.5% gap to the analyst target — but extreme pipeline and supplier concentration in single counterparties, quality far below investment-grade levels, and implied volatility at 154% make this a highly speculative binary setup rather than a conventional investment.
Thesis pillars
- Pipeline Supplier Concentration↑Improving
- Technical Momentum Breakout↓Deteriorating
- Cash Burning Pre Revenue Quality→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 3, 2026
Enliven Therapeutics, Inc. (ELVN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $44.78: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality.
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors, with ELVN-001 — a BCR-ABL inhibitor for chronic myeloid leukemia — as its sole active clinical program in the Phase 1 ENABLE trial. The company has no approved... Read more
Sell if holding. Engine safety override at $44.78: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Enliven Therapeutics, Inc.
About Enliven Therapeutics, Inc.
ELVN-001, Enliven Therapeutics' BCR-ABL tyrosine kinase inhibitor targeting chronic myeloid leukemia, had 90 patients enrolled in the Phase 1 ENABLE trial as of the April 28, 2025 data cutoff, with a reported cumulative major molecular response rate of 47% at 24 weeks across dose levels ranging from 10 mg once daily to 80 mg twice daily. The company reported a net loss of $103.7 million for the year ended December 31, 2025 and carries $347.2 million in accumulated deficit with no product revenue generated to date.
Enliven Therapeutics is a clinical-stage company financing operations entirely through equity issuances. ELVN-001 targets the BCR-ABL fusion gene — the oncogenic driver present in approximately 95% of CML patients diagnosed in chronic phase — as an ATP-competitive inhibitor designed to avoid the off-target kinase activity that causes cardiovascular and metabolic side effects in second-generation TKIs such as dasatinib and nilotinib. The company competes in a market currently anchored by Novartis' Scemblix (asciminib), which achieved a $1.6 billion annualized sales run-rate in the fourth quarter of 2025 with projected peak annual sales of $4 billion. GMP APIs for ELVN-001 are manufactured solely by Pharmaron; drug product is produced at Latitude Pharmaceuticals, Quotient Sciences, and CoreRx under contract manufacturing arrangements. The company is exploring strategic alternatives for ELVN-002, a HER2 inhibitor deprioritized in May 2025, concentrating all resources on ELVN-001 and the planned Phase 3 ENABLE-2 trial targeting second-line-plus CML patients.
Show full overview
The company's NPV is essentially a binary bet on ELVN-001 advancing through Phase 3. In January 2026, updated Phase 1b data from the 80 mg once-daily cohort (n=19) showed an MMR rate of 38% and deep molecular response rate of 16%, while the randomized 60 mg and 120 mg cohort (n=41) showed 53% MMR and 35% DMR at 24 weeks, comparing favorably to asciminib's pivotal trial precedent. FDA alignment on dose selection for ENABLE-2 is pending; any major protocol objection or Complete Response Letter could delay Phase 3 initiation beyond the planned second-half 2026 target, leaving the company to fund operations from existing capital while no revenue-generating path exists.
See also: Healthcare · Biotechnology
From Enliven Therapeutics, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-10-29Recent Developments — Enliven Therapeutics, Inc.
Latest news
- NEWS HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73 — benzinga Oct 19, 2026 positive
- NEWS Enliven Therapeutics Announces FDA Alignment On Phase 3 Relcobatinib Chronic Myeloid Leukemia Trial Design, Expects Star — benzinga Oct 6, 2026 positive
- NEWS This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday — benzinga Oct 2, 2026 positive
- NEWS Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70 — benzinga Oct 2, 2026 positive
- NEWS JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75 — benzinga Oct 1, 2026 positive
Generated 2026-10-29T12:43:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineELVN-00110-K Item 1A: 'we are substantially dependent on ELVN-001. If we are unable to advance ELVN-001 through clinical development, obtain regulatory approval and ultimately commercialize or license ELVN-001'
- HIGHSupplierPharmaron10-K Item 1: 'our good manufacturing practice ("GMP") APIs from Pharmaron'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $44.78: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $41.65. Score 5.6/10, moderate confidence.
Analyst target: $64.74 (+44.6% upside). Prior stop was $41.65. Stop-loss: $41.65.
Concentration risk — Pipeline: ELVN-001; Concentration risk — Supplier: Pharmaron; Quality below floor (1.6 < 4.0).
Enliven Therapeutics, Inc. trades at a P/E of N/A (forward -19.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover ELVN with a consensus score of 4.3/5. Average price target: $74.
What does Enliven Therapeutics, Inc. do?Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors, with...
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors, with ELVN-001 — a BCR-ABL inhibitor for chronic myeloid leukemia — as its sole active clinical program in the Phase 1 ENABLE trial. The company has no approved products and no revenue; it reported a net loss of $103.7 million in 2025 and carries $347.2 million in accumulated deficit.